DLD-1 Xenograft Model Service for Colon Cancer

The DLD-1 xenograft model is a well-established preclinical platform for colon cancer research, offering robust tumorigenicity and a clinically relevant molecular profile for evaluating therapeutic candidates. At Alfa Cytology, we provide comprehensive DLD-1 xenograft model services tailored to your drug development pipeline, delivering reproducible tumor data and customizable study designs to accelerate your preclinical research.

Overview of DLD-1 Xenograft Model for Colon Cancer

The DLD-1 cell line was established from a colorectal adenocarcinoma specimen obtained from an adult male patient and represents one of the most widely utilized models in colorectal cancer research. DLD-1 cells harbor key driver mutations including a heterozygous KRAS G13D activating mutation, inactivating mutations in the APC tumor suppressor gene, and TP53 alterations, closely mimicking the molecular landscape of chromosomal instability (CIN) subtype colorectal cancer observed in clinical settings. These cells exhibit epithelial morphology, express carcinoembryonic antigen (CEA), and demonstrate robust tumorigenic capacity in immunocompromised mice, making them an ideal substrate for xenograft studies.

In xenograft applications, DLD-1 tumors demonstrate consistent growth kinetics and are highly responsive to both standard chemotherapeutic agents and novel targeted therapies. The model has been extensively validated for evaluating anti-EGFR therapeutics, MEK inhibitors, and combination regimens. Subcutaneous implantation allows for straightforward tumor monitoring and high-throughput drug screening, while orthotopic implantation into the cecal or colonic wall preserves the native tumor microenvironment, enabling more physiologically relevant assessments of local invasion, stromal interactions, and locoregional therapy responses. Bioluminescent variants such as DLD-1-luc further enhance the model by enabling non-invasive longitudinal tracking of tumor burden through in vivo imaging systems.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting colorectal adenocarcinoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving colon cancer progression through KRAS, APC, and TP53 mutations, and how treatments intersect with these pathways.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment.

Figure 1. The levels of YAP expression are correlated with pronounced migration and invasion of CRC cell lines. (Takeda, T, et al., 2022)

Cell Line Information: DLD-1

The DLD-1 cell line is a well-established human colorectal adenocarcinoma line with comprehensive molecular characterization. Its KRAS G13D mutation, APC truncation, and CIN molecular subtype make it unique among available colon cancer cell lines and essential for preclinical research targeting the most common molecular subtype of colorectal carcinoma.

Our Services

Alfa Cytology leverages the DLD-1 xenograft model to deliver high-quality preclinical data for your colon cancer therapeutic programs. Our experienced team ensures rigorous quality control, from cell line authentication and mycoplasma testing to standardized tumor monitoring and comprehensive endpoint analysis, providing you with reliable, publication-ready results.

Workflow of DLD-1 Xenograft Model Construction

Alfa Cytology follows a standardized, IACUC-compliant workflow to construct DLD-1 xenograft models with high reproducibility and translational relevance. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Preparation and Quality Control: DLD-1 cells are maintained under exponential growth conditions in RPMI-1640 medium supplemented with 10% fetal bovine serum. Prior to injection, cells are harvested via trypsinization, and viability is confirmed using trypan blue exclusion (>=98% viability required). Mycoplasma testing and STR authentication are performed routinely to ensure cell line integrity.
2. Mouse Preparation and Acclimatization: Immunocompromised mice (athymic nude or NOD/SCID, 6--8 weeks old) are acclimatized to the vivarium environment for at least one week. Animals are sorted by body weight and examined daily for baseline health assessment prior to tumor cell injection.
3. Tumor Cell Injection: For subcutaneous models, a cell suspension of 1x10^6 DLD-1 cells in 100 uL of Matrigel/PBS (1:1) is injected into the hind flank. For orthotopic models, DLD-1 cells are surgically implanted into the cecal wall under anesthesia, enabling organ-specific tumor development.
4. Tumor Monitoring and Randomization: Injection sites are palpated three times weekly until tumors become palpable. Tumor dimensions are measured with digital calipers, and volume is calculated using the formula (length x width^2)/2. Once tumors reach 50--150 mm^3, animals are randomized into treatment cohorts.
5. Compound Administration: Test compounds are administered according to the predefined dosing schedule (e.g., intraperitoneal, intravenous, or oral gavage). Vehicle controls and positive controls are included in parallel to ensure assay validity.
6. Longitudinal Assessment: Tumor volumes and body weights are recorded at regular intervals throughout the study. Bioluminescent imaging is performed for orthotopic or luciferase-expressing models to track tumor progression non-invasively.
7. Endpoint Analysis and Necropsy: Animals are humanely euthanized when tumors reach the predetermined size limit (typically 2,000 mm^3) or at the study endpoint per IACUC protocol. Final necropsy includes tumor excision, weighing, digital imaging, and collection of tissues for histology, biomarker analysis, or gene expression profiling.

Figure 2: Schematic workflow illustrating the derivation and construction of the DLD-1 Xenograft Model at Alfa Cytology.

Case Study-DLD-1 Xenograft Model Development

Alfa Cytology has successfully developed and validated the DLD-1 xenograft model across multiple preclinical studies. Our internal data demonstrate consistent tumor growth kinetics, high take rates, and robust responsiveness to reference compounds including 5-fluorouracil and oxaliplatin. Detailed efficacy data, tumor growth curves, and pharmacodynamic biomarker profiles are available upon request. Contact our team to discuss your specific study requirements and receive a customized proposal.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your DLD-1 xenograft model ensures access to a scientifically rigorous, quality-driven preclinical service platform designed to advance your colon cancer therapeutic candidates efficiently.

• Verified Cell Line Integrity: Comprehensive cell line authentication and mycoplasma screening to ensure data integrity and reproducibility.
• High Take Rates and Consistency: Flexible study designs supporting both subcutaneous and orthotopic implantation with customizable endpoints.
• Integrated Imaging Capabilities: Real-time tumor monitoring using digital calipers and optional bioluminescence imaging for longitudinal tracking.
• Tailored Study Designs: GLP-compliant workflows and IACUC-regulated animal care meeting international preclinical standards.
• Standardized Protocols: Dedicated project management with timely reporting and publication-ready data packages.
• Dedicated Project Management: Competitive timelines and transparent pricing to accelerate your drug discovery pipeline.

Contact Us

Ready to advance your colon cancer preclinical research with the DLD-1 xenograft model? Reach out to our expert team at Alfa Cytology to discuss your project requirements, receive a tailored study proposal, and explore how our preclinical services can support your therapeutic development goals. Please reach out to us today via our inquiry form or email to learn more about our DLD-1 Xenograft Model services.

For research use only. Not intended for any clinical use.